← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
101	DMRA 101 Damora Therapeutics DMRA $1.14B	104	+39	+60%	$1.67B
102	102 Agenus AGEN $294M	103	+15	+17%	$43.6M
103	103 Bicycle Therapeutics BCYC $246M	103	+5	+5%	$158M
104	104 Foghorn Therapeutics FHTX $110M	102	-3	-3%	$219M
105	105 Inovio Pharmaceuticals INO $102M	102	+2	+2%	$36.1M
106	106 Century Therapeutics IPSC $250M	100	+28	+39%	$387M
107	107 Sutro Biopharma STRO $174M	100	+22	+28%	$546M
108	108 Black Diamond Therapeutics BDTX $97.7M	96	-8	-8%	$64.9M
109	109 Karyopharm Therapeutics KPTI $7.14M	96	+19	+25%	$207M
110	110 Monopar Therapeutics MNPR $491M	95	+13	+16%	$576M
111	111 ALX Oncology ALXO $124M	93	+24	+35%	$218M
112	112 Zai Lab ZLAB $2.53B	92	-7	-7%	$819M
113	113 TuHURA Biosciences HURA $112M	89	-1	-1%	$21M
114	114 Lyell Immunopharma LYEL $196M	87	+13	+18%	$178M
115	115 Pliant Therapeutics PLRX $54.7M	86	-5	-5%	$54.8M
116	116 Autolus Therapeutics AUTL $450M	83	-1	-1%	$212M
117	117 Compugen CGEN $189M	83	+4	+5%	$30.3M
118	118 Crescent Biopharma CBIO $467M	82	+19	+30%	$533M
119	119 Immatics IMTX $1.07B	82	-2	-2%	$1.01B
120	120 INmune Bio INMB $44.4M	82	0	0%	$7.08M
121	121 Nuvectis Pharma NVCT $588M	82	+20	+32%	$189M
122	122 Context Therapeutics CNTX $23.5M	79	+19	+32%	$34.8M
123	PBLS 123 Parabilis Medicines Inc PBLS $3.2B	79	+79	–	$2.71B
124	124 Eikon Therapeutics EIKN $380M	77	+25	+48%	$344M
125	125 Whitehawk Therapeutics WHWK $169M	77	+15	+24%	$198M